Aligos Therapeutics (ALGS) Other Non-Current Liabilities (2019 - 2024)

Aligos Therapeutics (ALGS) has 6 years of Other Non-Current Liabilities data on file, last reported at $72.4 million in Q4 2024.

• Quarterly Other Non-Current Liabilities rose 162.24% year-over-year to $72.4 million in Q4 2024, while the trailing twelve-month figure through Dec 2024 was $72.4 million (up 162.24% YoY) and the FY2024 annual result came in at $72.4 million, up 162.24% from the prior year.
• Other Non-Current Liabilities climbed to $72.4 million in Q4 2024, from $11.6 million in the prior quarter.
• In the past five years, Other Non-Current Liabilities ranged from a high of $72.4 million in Q4 2024 to a low of $133000.0 in Q4 2021.
• A 5-year average of $12.8 million and a median of $267000.0 in 2021 frame the typical range for Other Non-Current Liabilities.
• Annual changes were most pronounced in 2021 — Other Non-Current Liabilities sank 56.94% — and 2024, when it jumped 162.24%.
• Tracing ALGS's Other Non-Current Liabilities over 5 years: stood at $620000.0 in 2020, then tumbled by 78.55% to $133000.0 in 2021, then changed by 0.0% to $133000.0 in 2022, then jumped by 20648.87% to $27.6 million in 2023, then surged by 162.24% to $72.4 million in 2024.
• The last three Other Non-Current Liabilities figures came in at $72.4 million (Q4 2024), $11.6 million (Q3 2024), and $11.5 million (Q2 2024), per Business Quant data.